Innovative alternative to LNPs for mRNA therapeutics - In vivo-jetRNA®+

Lieferant: Polyplus-transfection
jetRNA®
101000122.EA 1710 CHF
101000122.
Innovative alternative to LNPs for mRNA therapeutics - In vivo-jetRNA®+
Transfektionsreagenzien
In vivo-jetRNA®+ is a ready-to-use, efficient and stable lipid-based transfection reagent optimised for in vivo mRNA delivery.

  • Efficient: 100% mRNA encapsulation leading to comparable LNP delivery results
  • Time saving: Ready-to-use reagent that does not require formulation equipment
  • Stable: Maintain liposome size using low to high mRNA concentration over time
  • Universal: Target any organ/tissue using various administration routes
  • Safe: Maintain healthy animals and organs

In vivo-jetRNA®+ is a lipid-based transfection reagent composed of preformed liposomes specifically developed to deliver mRNA in vivo. In vivo-jetRNA®+ has been carefully optimised by Polyplus and can be used with a simple and straightforward protocol without any formulation step (contrary to Lipid nanoparticles). This reagent can be used to target unique or multiple organs, by using systemic injection routes, in various animal models (mice, rat, etc.).

Zertifizierungen: Polyplus® has been an ISO 9001 accredited company since 2002. Since then this certification has been successfully renewed every three years.
Order Now

Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Mehr About VWR